These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 26122712)
1. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Rose TL; Deal AM; Basch E; Godley PA; Rathmell WK; Kim WY; Whang YE; Dunn MW; Wang A; Chen RC; Nielsen ME; Pruthi RS; Wallen EM; Woods ME; Smith AB; Milowsky MI Urol Oncol; 2015 Sep; 33(9):386.e1-6. PubMed ID: 26122712 [TBL] [Abstract][Full Text] [Related]
2. Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study. Hinata N; Hussein AA; George S; Trump DL; Levine EG; Omar K; Dasgupta P; Khan MS; Hosseini A; Wiklund P; Guru KA BJU Int; 2017 Apr; 119(4):605-611. PubMed ID: 27743481 [TBL] [Abstract][Full Text] [Related]
3. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y; Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010 [TBL] [Abstract][Full Text] [Related]
4. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. Martinez-Piñeiro JA; Gonzalez Martin M; Arocena F; Flores N; Roncero CR; Portillo JA; Escudero A; Jimenez Cruz F; Isorna S J Urol; 1995 Mar; 153(3 Pt 2):964-73. PubMed ID: 7853584 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473 [TBL] [Abstract][Full Text] [Related]
7. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804 [TBL] [Abstract][Full Text] [Related]
8. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698 [TBL] [Abstract][Full Text] [Related]
9. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU; Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383 [TBL] [Abstract][Full Text] [Related]
10. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838 [TBL] [Abstract][Full Text] [Related]
11. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024 [TBL] [Abstract][Full Text] [Related]
12. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718 [TBL] [Abstract][Full Text] [Related]
14. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]. Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M; Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925 [TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer. Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021 [TBL] [Abstract][Full Text] [Related]
17. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837 [TBL] [Abstract][Full Text] [Related]
18. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752 [No Abstract] [Full Text] [Related]
19. The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer. Ryan S; Serrell EC; Karabon P; Mills G; Hansen M; Hayn M; Menon M; Trinh QD; Abdollah F; Sammon JD J Urol; 2018 Feb; 199(2):424-429. PubMed ID: 29030318 [TBL] [Abstract][Full Text] [Related]
20. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. Faiena I; Salmasi A; Mendhiratta N; Lenis AT; Pooli A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K World J Urol; 2018 Nov; 36(11):1825-1833. PubMed ID: 29752514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]